Most triple negative (human epidermal growth factor receptor 2 (HER-2), progesterone receptor (PR), and estrogen receptor (ER) negative) breast cancers, as well as high-risk luminal HER-2 negative tumors, are treated with chemotherapy (Senkus et al. 2015). This evidence concerns the gene ESR1 and breast carcinoma.